HLS Therapeutics Inc.
HLTRF
$3.15
-$0.11-3.37%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.91% | -2.23% | -4.08% | -2.40% | 1.20% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.91% | -2.23% | -4.08% | -2.40% | 1.20% |
| Cost of Revenue | 9.29% | 1.25% | 3.67% | 3.98% | 26.16% |
| Gross Profit | -1.31% | -3.53% | -6.81% | -4.59% | -6.84% |
| SG&A Expenses | -4.75% | -15.62% | -18.11% | -19.67% | -19.52% |
| Depreciation & Amortization | 3.28% | 0.53% | 0.05% | -6.37% | -9.44% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.79% | -5.58% | -6.84% | -9.64% | -7.07% |
| Operating Income | -1.10% | 179.00% | 27.42% | 61.58% | 36.82% |
| Income Before Tax | 48.53% | 32.54% | 19.74% | -55.60% | 27.32% |
| Income Tax Expenses | 108.70% | -861.18% | 71.19% | -94.06% | 20.69% |
| Earnings from Continuing Operations | 48.22% | 55.84% | 19.12% | 51.76% | 27.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 48.22% | 55.84% | 19.12% | 51.76% | 27.35% |
| EBIT | -1.10% | 179.00% | 27.42% | 61.58% | 36.82% |
| EBITDA | 4.80% | 11.25% | 14.44% | 22.81% | 29.29% |
| EPS Basic | 47.38% | 60.00% | 18.11% | 51.65% | 27.04% |
| Normalized Basic EPS | 47.66% | 38.88% | 18.44% | 49.75% | 24.66% |
| EPS Diluted | 47.57% | 61.94% | 18.11% | 50.00% | 26.78% |
| Normalized Diluted EPS | 47.66% | 38.88% | 18.44% | 49.75% | 24.66% |
| Average Basic Shares Outstanding | -1.63% | 10.40% | -1.23% | -0.24% | -0.46% |
| Average Diluted Shares Outstanding | -1.63% | 10.40% | -1.23% | -0.24% | -0.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |